Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab withdrawal for ulcerative colitis in remission
jRCTs021210073Completed
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ustekinumab in autoimmune colitis. Primary endpoints: Relapse of ulcerative colitis at 2 years after ustekinumab discontinuation and Remission after ustekinumab intravenous re-induction. Started Mar 2022; status: completed.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCTs021210073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210073.